UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION IV
611 RYAN PLAZA DRIVE, SUITE 400
ARLINGTON, TEXAS 76011-4005

December 28, 2004

Rapid City Regional Hospital, Inc.
ATTN: Ed Cytacki, Ph.D.
Radiation Safety Officer
353 Fairmont Blvd.
Rapid City, SD 57701

SUBJECT: LICENSE AMENDMENT

Please find enclosed Amendment No. 73 to NRC License No. 40-00238-04. **This amendment acknowledges the change of the certifying officer to Mr. Michael Gibbs and this amendment adds Dr. Leo Flynn as an authorized user.** An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14)(iv). You should review the enclosed document carefully and be sure that you understand all conditions. If there are any errors or if you have any questions, contact me at 817-860-8132.

NRC expects licensees to conduct their programs with meticulous attention to detail and a high standard of compliance. Because of the serious consequences to employees and the public that can result from failure to comply with NRC requirements, you must conduct your radiation safety program according to the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate by NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers: Inspection and Investigations," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.

2. Notify NRC in writing of any change in mailing address.

3. By 10 CFR 30.36(d) and/or license condition, notify NRC, promptly, in writing, and request termination of the license:

   a. When you decide to terminate all activities involving materials authorized under the license whether at the entire site or any separate building or outdoor area;

   b. If you decide not to acquire or possess and use authorized material; or

   c. When no principal activities under the license have been conducted for a period of 24 months.

4. In accordance with 10 CFR 35.14, notify the NRC no later than 30 days after:

   a. The date that the licensee permits an individual to work as an authorized user, an authorized nuclear pharmacist or an authorized medical physicist under 10 CFR 35.13(b)(1) through (b)(4);

b. An authorized user, an authorized nuclear pharmacist, a Radiation Safety Officer, or an authorized medical physicist permanently discontinues duties under the license or has a name change;

c. The licensee's mailing address changes;

d. The licensee's name changes, but the name change does not constitute a transfer of control of the license as described in 10 CFR 30.34(b); or

e. The licensee has added to or changed the areas of use identified in the application or on the license where byproduct material is used in accordance with either 35.100 or 35.200.

5. Request and obtain a license amendment before you:

a. Change Radiation Safety Officers;

b. Order byproduct material in excess of the amount, radionuclide or form authorized on the license;

c. Add or change the areas or address(es) of use identified in the license application or on the license, except for areas of use where byproduct material is used only in accordance with either 10 CFR 35.100 or 35.200; or

d. Change the name or ownership of your organization.

6. Submit a complete renewal application or termination request at least 30 days before the expiration date on your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of radioactive material after your license expires is a violation of NRC regulations.

In addition, please note that NRC Form 313 requires the applicant, by signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant. Since the NRC also accepts a letter requesting amendment of an NRC license, the signatory for such a request should also be the licensee or certifying official rather than a consultant.

NRC will periodically inspect your radiation safety program. Failure to conduct your program according to NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC may result in enforcement action against you. This could include issuance of a notice of violation; imposition of a civil penalty; or an order suspending, modifying, or revoking your license as specified in the "General Statement of Policy and Procedure for NRC Enforcement Actions" (Enforcement Policy), NUREG 1600.

The NRC no longer publishes the NRC Rules and Regulations loose leaf supplements due to budget constraints. However, an electronic version of the NRC's regulations is available on the NRC Web site at www.nrc.gov. To view these regulations, highlight "Electronic Reading Room" and choose "Regulations" on the drop down menu. An electronic version of the NUREG-1556 Series publications is also available on the NRC Web site. To view these guidance documents, highlight "Electronic Reading Room"; choose "All Document Types" on the drop down menu; scroll down to "NUREG-Series Publications"; and select "Publications Prepared by the NRC Staff". Then, choose "NUREG-1556" from the table and select the appropriate volume(s) for your license type.

In accordance with 10 CFR 2.390 of the NRC's "Rules of Practice," a copy of this letter and its enclosure will be available electronically for public inspection in the NRC Public Document Room or from the NRC's document system (ADAMS). ADAMS is accessible from the NRC Web site at http://www.nrc.gov/reading-rm/adams.html.

Please note that on October 25, 2004, the NRC suspended public access to ADAMS, and initiated an additional security review of publicly available documents to ensure that potentially sensitive information is removed from the ADAMS database accessible through the NRC's web site. Interested members of the public may obtain copies of the referenced documents for review and/or copying by contacting the Public Document Room pending resumption of public access to ADAMS. The NRC Public Document Room is located at NRC Headquarters in Rockville, MD, and can be contacted at 800-397-4209 or 301-415-4737 or pdr@nrc.gov.

Thank you for your cooperation.

Sincerely,

/RA/

Jacqueline D. Cook, Senior Health Physicist
Nuclear Materials Licensing Branch

Docket: 030-03231
License: 40-00238-04
Control: 470229

Enclosures: As stated

MATERIALS LICENSE

Amendment No. 73

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated October 12, 2004
1. Rapid City Regional Hospital, Inc.	3. License number 40-00238-04 is amended in its entirety to read as follows:
2. 353 Fairmont Blvd Rapid City, South Dakota 57701	4. Expiration date October 31, 2010
	5. Docket No. 030-03231 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. As needed (no single container to exceed 300 milliCuries)
D. Any byproduct material identified in 10 CFR 35.400	D. Any brachytherapy source identified in 10 CFR 35.400	D. As needed
E. Iridium-192, as permitted by 10 CFR 35.600	E. Sealed sources (Nucletron Model No. 105.002, manufactured by Mallinckrodt Medical BV or AEA Technology, Inc.)	E. 2 sources not to exceed 12 curies each.
F. Strontium-90	F. Sealed sources (BEBIG Model Sr0.S03)	F. 12 sources per 30 mm train, not to exceed 4.2 milliCuries mean activity per source, 51 milliCuries total per source train; 4 source trains
G. Any byproduct material identified in 10 CFR 31.11	G. Prepackaged Kits	G. As needed

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
40-00238-04

Docket or Reference Number
030-03231

Amendment No. 73

9. Authorized use:

   A. Medical use described in 10 CFR 35.100.
   B. Medical use described in 10 CFR 35.200.
   C. Medical use described in 10 CFR 35.300.
   D. Medical use described in 10 CFR 35.400 and, for cesium-137, calibration of licensee's survey meters and personnel dosimeters.
   E. One source for medical use, as permitted by 10 CFR 35.600, in a Nucletron MicroSelectron-HDR Model 105.999 remote afterloading brachytherapy device. One source (not to exceed 12 curies while stored pending installation) in a shipping container for source replacement.
   F. Notwithstanding the requirements of 10 CFR 35.400, for use in Novoste Beta-Cath System Model A1732 device for intravascular brachytherapy.
   G. In vitro studies.

CONDITIONS

10. Licensed material may be used only at the licensee's facilities located at 353 Fairmont Blvd., Rapid City, South Dakota.

11. The Radiation Safety Officer for this license is Ed Cytacki, Ph.D.

12. The Medical Physicist for this license is Ed Cytacki, Ph.D.

13. Authorized Users:

   A. Thomas G. Habbe, M.D., for material identified in 10 CFR 35.100, 35.200 and 35.300.

   B. Ronald G. Drummond, M.D., for material identified in 10 CFR 35.300 and 35.400; Iridium-192 for HDR radiotherapy; and Strontium-90 for manual intravascular brachytherapy.

   C. Daniel M. Tackett, M.D., for material identified in 10 CFR 35.300 and 35.400; Iridium-192 for HDR radiotherapy; and Strontium-90 for manual intravascular brachytherapy.

   D. Timothy R. Frost, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300 and 31.11.

   E. Dennis E. Nesbit, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300 and 31.11.

   F. Jon R. Stenberg, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300 and 31.11.

   G. Donald M. Habbe, M.D., for material identified in 10 CFR 31.11.

   H. Robert Durst, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300 and 31.11.

   I. Rebecca Belsaas, M.D., for material identified in 10 CFR 35.100, 35.200 and 35.300.

   J. William Zavitz, M.D., for material identified in 10 CFR 35.100, 35.200 and 35.300.

   K. Ronald Baxter, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300 and 31.11.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
40-00238-04

Docket or Reference Number
030-03231

Amendment No. 73

L. Daniel Petereit, M.D., for material identified in 10 CFR 35.300 and 35.400; Iridium-192 for HDR radiotherapy; and Strontium-90 for manual intravascular brachytherapy.

M. Donald Pansegrau, M.D., for material identified in 10 CFR 35.200.

N. Amad Zineldine, M.D., for material identified in 10 CFR 35.200.

O. Brian R. Baxter, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300, and 31.11.

P. Leo P. Flynn, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300, and 31.11.

14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Letter dated May 19, 1999
B. Application dated June 16, 2000
C. Letter dated March 5, 2001
D. Letter dated July 6, 2001, except Quality Management Program (QMP)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

/RA/

Date: December 28, 2004

By: _____

Jacqueline D. Cook, Senior Health Physicist
Nuclear Materials Licensing Branch
Region IV
Arlington, Texas 76011